Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
|Articles|April 5, 2023
Pharma USA 2023: IRA Impact on Patients
Advertisement
Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on Medicare patients' affordability.
Advertisement
Related to this article
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.
Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
4
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
5